Sera Prognostics Inc., The Pregnancy Company, focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, announced that Scott Gleason has been appointed Chief Financial Officer (CFO), effective August 31, 2026.
Mr. Gleason brings more than 25 years of healthcare, diagnostics, and capital markets experience to Sera. Most recently, he served as Vice President of Investor Relations and Treasury at Neogen Corporation and previously served as CFO of LarmorBio and NX Prenatal. He also served as the interim CFO of OraSure Technologies, helping to scale the company’s COVID-19 test to a multi-hundred-million-dollar product. Prior to OraSure, he led corporate strategy and investor relations at Myriad Genetics. His combination of financial leadership, capital markets expertise, and strategic perspective will support Sera’s next stage of commercial development. Mr. Gleason holds a B.S. in Economics from the United States Air Force Academy.
“Scott brings financial leadership, operating discipline, and capital markets experience that will support Sera’s continued growth and execution,” said Zhenya Lindgardt, Chief Executive Officer of Sera. “As we continue expanding access to the PreTRM Test and advancing our commercialization efforts, his unique combination of CFO experience, investor relations expertise, and strategic leadership will be an important asset as we strengthen commercial execution and support our business priorities.”
“I am exceptionally excited to join the team at Sera. Preterm birth remains one of the largest areas of unmet medical need in our healthcare system with significant opportunity to drive value for patients, payers, and physicians,” said Mr. Gleason. “Sera has built a strong commercial foundation, generated gold standard evidence supporting the value of the PreTRM test and has a significant opportunity to establish this product as the standard of care for all pregnant women. I look forward to partnering with the leadership team to support this important mission.”
Austin Aerts, who has served as Chief Financial Officer since June 2023, will transition to an advisory capacity focused on strategic initiatives and ensuring continuity. Since joining the company in 2017, he has held a series of finance leadership positions and played a pivotal part in guiding Sera through its successful initial public offering and transition to the public markets. Austin played a critical role in the company’s financial strategy, operational readiness, and execution throughout the IPO process, contributing significantly to Sera’s successful transition to the public markets and helping establish the foundation for the company’s next phase of growth as a public company. In his advisory role, he will continue to provide strategic support and institutional knowledge as the company moves through the transition.
“Austin has been an exceptional partner and leader throughout his time at Sera,” said Ms. Lindgardt. “Since joining the company over nine years ago, including serving as CFO, his dedication, financial leadership, and deep understanding of our business have been instrumental to Sera’s growth and evolution. We are grateful for his many contributions and look forward to continuing to partner with him to grow Sera’s business.”
For more information, please visit these web pages:
First Fertility Appoints Alison Bartolucci as New Chief Scientific Officer
re-centre Launches Groundbreaking Hypopressives App to Transform Postnatal Recovery
